Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

February 18, 2021

Study Completion Date

November 4, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

Elotuzumab according to dosing schedule outlined in treatment arms.

DRUG

Lenalidomide

Lenalidomide according to dosing schedule outlined in treatment arms.

DRUG

Dexamethasone

"Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert."

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER